Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

FPMI Names Edward L. Lyons to Newly Created Position of Vice President, Marketing

Published: Tuesday, October 29, 2013
Last Updated: Tuesday, October 29, 2013
Bookmark and Share
Broad healthcare industry and global experience will advance FluoroPharma's nuclear cardiology strategy and strengthens goal for commercialization in 2016.

FluoroPharma Medical, Inc. has announced that Edward L. Lyons, GE Healthcare's Global Marketing Director, Nuclear Medicine, has been named to FluoroPharma's newly created position of Vice President, Marketing.

Mr. Lyons will be responsible for the global development and commercial strategy for FluoroPharma's nuclear cardiology portfolio and will report directly to FluoroPharma's Chairman and CEO, Thijs Spoor.

"We are delighted that Ed Lyons, a distinguished healthcare veteran with vast experience in nuclear cardiology across the health care continuum, from hospital to pharmaceuticals and diagnostics; and with the expertise to develop strategic and operational programs that drive growth, has joined our company at such a defining moment in our evolution. Today's announcement reflects the confidence we have in our vision to enable personalized medicine through precision diagnostics, the strength of our science and the promise of our portfolio. We created this position to manage our global strategies, advance our approach to launching, marketing and selling our products as well as strengthening our potential for strategic partnerships," said Mr. Spoor.

"I am excited to be a member of the FluoroPharma team and look forward to contributing to our success. My career has been devoted to diagnostic imaging, and PET is ideal for the early detection and diagnosis of diseases. I believe that the development of new molecular diagnostic imaging agents will extend the utility of PET, while helping to address the global economic challenges of healthcare delivery. FluoroPharma's diagnostics could provide better information for clinicians that will further enable doctors and patients to make more informed choices on treatment. I believe FluoroPharma's pipeline holds great promise, I am confident we have the tools to make the promise become the reality," said Mr. Lyons.

Prior to joining FluoroPharma, Mr. Lyons was with GE Healthcare where he held management positions of increasing responsibility, culminating in his appointment to Global Marketing Director, Nuclear Medicine, where he was responsible for the worldwide marketing of the general purpose, hybrid imaging and direct-conversion detector camera portfolios.

During his tenure with GE Healthcare, Mr. Lyons successfully launched AdreView ™ and was responsible for the Cardiology commercial and development portfolios. In 2008, the business received the Frost and Sullivan Award for Radiopharmaceutical Marketing Excellence.

Before GE Healthcare, Mr. Lyons was with Bristol-Myers Squibb Medical Imaging, where he held positions in Medical Affairs Field Operations and Marketing. Prior to Bristol-Myers, Mr. Lyons was with DuPont Pharmaceuticals, where over the span of ten years he held positions in Nuclear Cardiology ranging from Sales and Marketing to Medical Affairs, where he was appointed to Director.

Mr. Lyons began his career within the hospital environment, where he was Chief Technologist in Nuclear Medicine and Nuclear Cardiology at Philadelphia Heart Institute, and Temple University Hospital.

Throughout his career, Mr. Lyons has contributed to numerous publications and white papers, and has presented on a variety of medical imaging topics at prestigious industry conferences and meetings.

Mr. Lyons has a diverse educational background in Management Theory and Practice, Marketing Excellence, Strategic Planning and Six Sigma. He holds active board certifications from Temple University School of Nuclear Medicine Technology and Albert Einstein School of Radiologic Technology.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FluoroPharma Expands Technology Platform to Include Agents for Alzheimer's Disease
FluoroPharma signs licensing agreement with MGH for the development and commercialization of agents for diagnosis and treatment of Alzheimer's disease.
Thursday, March 27, 2008
Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Bioreactors Ready for the Big Time
Bioreactors are passive filtration systems that can reduce nitrate losses from farm fields.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!